Clinical Trials · NCT03997539
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Sun Yat-sen University
- Enrollment
- 256
- Start date
- Aug 2019
- Locations
- See registry
- Primary endpoint
- maximum-tolerated dose (MTD)